gefitinib
survival
prognosis
outcome
prognostic
clinical
kinase
resistance
therapy
Gleason
treatment
targets
advance
associate
benefit
ci
disease
drugs
effect
factor
OS
recurrence
recurrence-free
trastuzumab
trial